Standard BioTools Management
Management criteria checks 2/4
Standard BioTools' CEO is Michael Egholm, appointed in Apr 2022, has a tenure of 2.67 years. total yearly compensation is $1.93M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $1.20M. The average tenure of the management team and the board of directors is 0.3 years and 1.8 years respectively.
Key information
Michael Egholm
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 30.9% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | less than a year |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
After Leaping 35% Standard BioTools Inc. (NASDAQ:LAB) Shares Are Not Flying Under The Radar
Dec 17
Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?
Oct 26Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher
Sep 14Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 05Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%
Jul 26Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?
Apr 09Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)
Mar 06Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable
Feb 17Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?
Jan 12Is Standard BioTools (NASDAQ:LAB) A Risky Investment?
Aug 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$171m |
| Jun 30 2024 | n/a | n/a | -US$165m |
| Mar 31 2024 | n/a | n/a | -US$136m |
| Dec 31 2023 | US$2m | US$597k | -US$75m |
| Sep 30 2023 | n/a | n/a | -US$76m |
| Jun 30 2023 | n/a | n/a | -US$84m |
| Mar 31 2023 | n/a | n/a | -US$131m |
| Dec 31 2022 | US$16m | US$373k | -US$190m |
Compensation vs Market: Michael's total compensation ($USD1.93M) is below average for companies of similar size in the US market ($USD3.24M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Egholm (61 yo)
2.7yrs
Tenure
US$1,931,088
Compensation
Dr. Michael Egholm, Ph.D. served as the President of Biopharmaceuticals and Senior Vice President at Pall Corporation since July 2014 until January 17, 2017. He serves as Director at Abbratech, Inc. and Ab...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$1.93m | 0.16% $ 1.2m | |
| Chief Financial Officer | less than a year | US$909.79k | 0.057% $ 422.1k | |
| VP & Chief Accounting Officer | less than a year | no data | no data | |
| Investor Relations | no data | no data | no data | |
| Chief Business Officer & Senior VP | no data | no data | 0.16% $ 1.2m | |
| Chief Medical Officer | no data | no data | no data |
0.3yrs
Average Tenure
57yo
Average Age
Experienced Management: LAB's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$1.93m | 0.16% $ 1.2m | |
| Independent Director | 1.8yrs | US$311.83k | 0.012% $ 88.8k | |
| Independent Director | 2.7yrs | US$173.50k | 0.019% $ 138.9k | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 2.7yrs | US$163.50k | 0.73% $ 5.4m | |
| Independent Chairman of the Board | less than a year | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | 0.026% $ 189.9k |
1.8yrs
Average Tenure
61.5yo
Average Age
Experienced Board: LAB's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:11 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Standard BioTools Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |
| Shawn Bevec | Deutsche Bank |